The U.K. is more centralized than any other major power. While many in Scotland want to escape London's grip, freedom has its consequences
The most profitable private equity deal in history was badly timed but brilliantly executed
Patrick Campbell, uranium smuggler—or patsy in a Homeland Security sting?
South Korea wants its robotics industry to surpass those in Europe, Japan, and the U.S.
A ruinous Fed policy? Tell that to investors who made a trillion off Treasuries
Designers weigh in on the long-awaited Apple Watch—and wish it weren't another timid rectangle
The $182.5 million deal puts an end to years of legal wrangling
The Whitman School of Management will assign undergrads to "houses" and they'll compete for points
Women make up about 20 percent of both the entrepreneurs and investors involved in angel investment deals, up from single digits a decade ago
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."